TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32185203
Drug: non-HA-coated implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-HA-coated implants
Study: 33416500
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment
Study: 36000541
Drug: Zanidatamab plus
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanidatamab plus chemotherapy + tislelizumab
Study: 38953334
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT)
Study: 38330377
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: 34919827
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy (PORT) at a dose of 54 Gy in 27 or 30 daily fractions, on five consecutive days a week.
Study: 36053867
Drug: Digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive behavioural therapy for insomnia (dCBT-I)
Study: 33089502
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme (ACE) inhibitors
Study: 38832504
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg twice daily
Study: 32576287
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (Paracetamol/Orphenadrine combination)
Study: 33542175
Drug: Oral oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxytocin (24IU)
Study: 33705565
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution
Study: 35289915
Drug: G-CSF prophylaxis
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF prophylaxis with FOLFIRI/nab-paclitaxel
Study: 32544560
Drug: Bimatoprost implant
Normalized name: bimatoprost Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost implant 15 μg
Study: 35025538
Drug: Lifestyle medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle medicine intervention (LMG; n = 39; eight weekly sessions)
Study: 34033146
Drug: Low-intensity exercise
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity exercise control (Buff Bones® [BB]) with antiresorptive medication
Study: 34533786
Drug: Tralokinumab 300
Normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 300 mg every 2 weeks
Study: 36371675
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia (propofol maintenance)
Study: 38254147
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy
Study: 36747363
Drug: Drug-Eluting Stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stents (DES)
Study: 35908682
Drug: Mechanical instrumentation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical instrumentation with adjunct photodynamic therapy (PDT)
Study: 2010154965
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (BTIs)
Study: 34655304
Drug: Buccal mucosa
Normalized name: Diazepam 5 MG Buccal mucosa Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal mucosa graft (BMG)
Study: 39217809
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments
Study: 34746745
Drug: 105 mg
Normalized name: menthol 105 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg of Depo-Provera
Study: 37039792
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril
Study: 39008236
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Lispro
Study: 38778803
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment
Study: 32861144
Drug: HAART treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART treatment for 48 weeks
Study: 37611354
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy
Study: 33300437
Drug: Individualized antiplatelet
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized antiplatelet therapy based on CYP2C19 genotyping (IA group)
Study: 33155236
Drug: Conventional antiplatelet
Normalized name: magaldrate and antiflatulents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiplatelet therapy (CA group)
Study: 36399673
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily for three weeks
Study: 34895119
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid treatment (5 mg daily for 3 months)
Study: 39626074
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups
Study: 33186312
Drug: Nonremoval of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonremoval of the blocker at the end of the pilot tube
Study: 36207063
Drug: Fosphenytoin (FPHT)
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosphenytoin (FPHT) at 22.5 mg/kg
Study: 36502794
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen
Study: 38600471
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment
Study: 32736891
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continued insulin therapy
Study: 34671998
Drug: Convex combination
Normalized name: CONVEX INSERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convex combination estimator
Study: 32430458
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine 300 units/mL (Gla-300)
Study: 32430458
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine 100 units/mL (Gla-100)
Study: 34233989
Drug: Common elements-based
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common elements-based intervention (15 individual sessions on a monthly basis)
Study: 36314980
Drug: Preoperative umbilicus
Normalized name: Umbilicus rupestris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative umbilicus preparation 30 minutes before surgery
Study: 33849683
Drug: Amphetamine 5
Normalized name: amphetamine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine 5 mg
Study: 32640131
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention administered by specially trained nurses
Study: 33516027
Drug: Dietary CP
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary CP content of 120 g CP/kg DM
Study: 33766820
Drug: Nasal fentanyl
Normalized name: fentanyl Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal fentanyl (NF) administered by lay carers
Study: 35851031
Drug: Oral metformin
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metformin hydrochloride 500 mg tablets, taken three times a day for 4 months
Study: 34518679
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (all doses)
Study: 37062416
Drug: Solvent-based paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solvent-based paclitaxel (175 mg/m2 q2w)
Study: 34305809
Drug: Low-dosage therapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage therapy
Study: 32507404
Drug: Patient-specific implant
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific implant (PSI)
Study: 34305238
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of bupivacaine and 3 μg of sufentanil
Study: 38251791
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg
Study: 33146778
Drug: Single-dose DEC
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose DEC (6 mg/kg body weight)
Study: 38687481
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy
Study: 39528108
Drug: β-blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers
Study: 32232659
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve block (FNB) with 0.5% levobupivacaine 15 ml
Study: 34535037
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg bid
Study: 34535037
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of apixaban
Study: 33939649
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% in water (40 mL) (placebo)
Study: 32951537
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus aspirin
Study: 36374501
Drug: Vaginal estradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estradiol tablet (10 μg/d for 2 weeks and then twice weekly) plus placebo gel (3 times weekly)
Study: 36151448
Drug: Sound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sound therapy combined with drug therapy (SDT)
Study: 37967350
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment
Study: 39602630
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: 36322845
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids at a dose of 1 g per day for 5 days after birth
Study: 33968064
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy (ART)
Study: 35513899
Drug: Twice-daily fixed
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily fixed combination of Bimatoprost 0.01%, Brimonidine 0.15%, and Timolol 0.5%
Study: 35513899
Drug: Twice-daily fixed
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily fixed combination
Study: 32374504
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by surgery (NACS)
Study: 32036959
Drug: HELP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HELP + RSV diet (400 mg/kg)
Study: 34785173
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil (6 mg as a bolus before reperfusion, followed by 48 hours of continuous infusion at a dose of 6 mg/h)
Study: 33292629
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control
Study: 33848338
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A vs Treatment B
Study: 32674792
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg daily prior to completion of gestational week 10, maintained through pregnancy
Study: 32674792
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) alone (after excluding 9 mothers on confounding medications)
Study: 36229537
Drug: Low-dose triple
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose triple combination polypill (telmisartan-20mg/amlodipine-2.5 mg/chlorthalidone-12.5 mg)
Study: 39363095
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy
Study: 35257498
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of therapy
Study: 35347418
Drug: Live music
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live music therapy (4-week duration)
Study: 39589730
Drug: Oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroids
Study: 37584273
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment
Study: 32166624
Drug: Low-dose amitriptyline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amitriptyline (25 mg once daily before bedtime)
Study: 36266008
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy
Study: 32619524
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous (IV) thiamine
Study: 36044097
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy (warm white-light exposure at 10,000 lx for 30 min per day for 12 weeks)
Study: 32043417
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) - dose-optimised (30–70 mg/day) or fixed-dose (70 mg/day)
Study: 32759251
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at a dose of 30 mg/kg
Study: 37203336
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin
Study: 35604539
Drug: Subcutaneous ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous ofatumumab 20 mg administered via an autoinjector pen (test formulation)
Study: 32247559
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg/day)
Study: 33643905
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT)
Study: 35132875
Drug: Genotype-guided P2Y12
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided P2Y12 inhibitor selection
Study: 36205036
Drug: Interrupted Sitting
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interrupted Sitting (3-min of moderate-intensity walking every 30 min for 3 h daily)
Study: 32463593
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate ODT (50 mg) with water
Study: 35970829
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of exercise and liraglutide
Study: 39357788
Drug: Proton Beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Beam Therapy (PBT)
Study: 35277071
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose iron and curcumin placebo (FS18_Plac)
Study: 34318597
Drug: Inhaled nezulcitinib
Normalized name: NEZULCITINIB
DrugBank: TD-0903 (DB16463)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nezulcitinib (1 mg)
Study: 36306974
Drug: CureSight treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CureSight treatment (90 minutes/day, 5 days/week for 16 weeks)
Study: 35459718
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (LLT)
Study: 39402005
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy
Study: 39570213
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT)
Study: 35623863
Drug: Ziziphus jujube
Normalized name: Ziziphus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziziphus jujube (30 g daily for 12 weeks)
Study: 39039666
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy
Study: 38934799
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone
Study: 36222880
Drug: 10mg dose
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg dose of amiloride
Study: 36469320
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium butyrate, 20 mg/kg body weight per day for 6 months
Study: 36469320
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium butyrate
Study: 35340223
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate tablets combined with ShenQu Xiaoshi oral liquid
Study: 34959923
Drug: AP collagen
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP collagen peptides (APCPs) 1000 mg
Study: 36782093
Drug: Sotagliflozin 400
Normalized name: sotagliflozin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotagliflozin 400 mg
Study: 39741323
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU)
Study: 35443784
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 50 mg b.i.d.
Study: 34491650
Drug: Conventional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosage reduction method (sertraline hydrochloride reduced by 25% every week)
Study: 34491650
Drug: Conventional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosage reduction method
Study: 33316557
Drug: Cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chemotherapy
Study: 39285365
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual (TAU)
Study: 35177277
Drug: Olaparib (OLA)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (OLA) monotherapy in BRCA-mutated PROC
Study: 37616221
Drug: Quadrivalent Influenza
Normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent Influenza HA vaccine (QIV)
Study: 35882814
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (3 g per packet, 1 packet per day for 2 weeks)
Study: 35422183
Drug: Glyphosate low
Normalized name: glyphosate
DrugBank: Glyphosate (DB04539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyphosate low dose of 36.0 g a.e. ha‐1
Study: 33812261
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (ozonated water at 25 µg/mL concentration and ozone gas)
Study: 33965594
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids
Study: 34444526
Drug: Variable-rate feedback
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable-rate feedback infusion (VFIM)
Study: 34531021
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg